Vestcor Inc Acquires 1,135 Shares of United Therapeutics Corporation $UTHR

Vestcor Inc raised its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 59.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,056 shares of the biotechnology company’s stock after acquiring an additional 1,135 shares during the quarter. Vestcor Inc’s holdings in United Therapeutics were worth $1,281,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. WealthCollab LLC raised its holdings in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. boosted its holdings in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares in the last quarter. Wilmington Savings Fund Society FSB increased its position in United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after buying an additional 49 shares during the last quarter. Abich Financial Wealth Management LLC acquired a new position in United Therapeutics during the third quarter worth $44,000. Finally, Geneos Wealth Management Inc. raised its holdings in United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

UTHR has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. TD Cowen increased their price objective on United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Royal Bank Of Canada raised their price objective on United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. HC Wainwright upped their target price on United Therapeutics from $525.00 to $600.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $539.00.

Insider Activity

In other news, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $539.54, for a total transaction of $5,125,630.00. Following the completion of the transaction, the chief executive officer directly owned 130 shares in the company, valued at $70,140.20. The trade was a 98.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ray Kurzweil sold 4,910 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $489.02, for a total value of $2,401,088.20. Following the completion of the sale, the director directly owned 12,670 shares of the company’s stock, valued at $6,195,883.40. This represents a 27.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 342,947 shares of company stock worth $167,479,373 over the last 90 days. Company insiders own 10.30% of the company’s stock.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: NEJM publishes full Phase 3 TETON-2 results showing nebulized Tyvaso met its primary endpoint in IPF, providing clear clinical validation for an important label expansion that can drive revenue upside. TETON-2/NEJM
• Positive Sentiment: Analyst/upgrades and constructive research: several brokers have raised price targets and buy ratings recently (RBC, TD Cowen, UBS among others), supporting a higher valuation and reinforcing upside expectations. Analyst Coverage
• Positive Sentiment: Pipeline derisking commentary and a Seeking Alpha upgrade highlight ralinepag’s Phase 3 success and call out meaningful longer-term upside (base-case fair value cited materially above current levels), which can lift sentiment on growth prospects. Seeking Alpha
• Positive Sentiment: Institutional accumulation: large funds (Wellington, Norges Bank, Darwin Global, Invesco, Avoro) have recently increased positions, which supports liquidity and longer-term investor confidence. Institutional Holdings
• Neutral Sentiment: Market commentary: coverage (e.g., Zacks) notes recent outsized intraday moves and volume spikes but cautions that revised earnings estimates may limit immediate follow-through; useful for trade/timing perspective rather than fundamental change. Zacks
• Negative Sentiment: Significant insider selling: CEO Martine Rothblatt executed multiple large sales (3/6, 3/9 and 3/11 filings) totaling many thousands of shares, leaving a small residual holding; large timed sales can create short-term headline pressure even if for personal/liquidity reasons. SEC filings: 3/11 3/11 SEC, 3/9 3/9 SEC, 3/6 3/6 SEC

United Therapeutics Price Performance

United Therapeutics stock opened at $544.71 on Thursday. The firm has a market cap of $23.87 billion, a price-to-earnings ratio of 19.52, a P/E/G ratio of 1.93 and a beta of 0.84. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $548.12. The firm has a fifty day moving average price of $484.97 and a two-hundred day moving average price of $458.01.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The company had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the prior year, the company earned $6.19 earnings per share. As a group, sell-side analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.